首頁 > 市場調查報告書 > 製藥

DDS

市場調查報告書

商品編碼

2039032

非專利抗癌無菌注射市場：依產品類型、疾病、通路及地區分類。

Generic Oncology Sterile Injectables Market, By Product Type, By Disease Indication, By Distribution Channel, By Geography

出版日期: 2026年04月07日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2026年，非專利無菌抗癌注射劑市場規模估計為358億美元，預計2033年將達689億美元。預計2026年至2033年，該市場將以9.8%的複合年成長率成長。

分析範圍		分析詳情
基準年	2025	市場規模（2026 年）	358億美元
效能數據	2020-2024	預測期	2026-2033
預測期（2026-2033 年）複合年成長率	9.80%	預計金額（2033 年）	689億美元

非專利無菌注射用抗癌藥物用於治療多種癌症，包括卵巢癌、乳癌和肺癌。與品牌藥相比，非專利無菌注射用抗癌藥物價格相對低廉。治療費用是癌症患者，尤其是印度、巴西和中國等新興國家患者的主要擔憂。因此，這些國家的政府正在努力降低藥品價格並改善藥品的可及性。例如，印度國家藥品價格管理局（NPPA）於2017年3月將部分抗癌藥物的價格降低了86%。

在患者群體龐大但購買力相對較低的國家，非專利仿製抗癌注射劑具有巨大的市場潛力。此外，專利到期將在預測期內推動非專利仿製抗癌注射劑市場的成長。生物相似藥的出現也對非專利 and Biosimilars Initiative，2017）的數據，生物相似藥分別自2013年和2015年起在歐洲和美國佔據了較大的市場佔有率，預計其在生物製藥市場的佔有率將顯著成長。最終，這將推動非專利仿製抗癌注射劑市場的成長。

市場動態

隨著癌症患者人數的不斷增加，非專利仿製抗癌注射市場也呈現顯著成長。例如，根據世界衛生組織（世衛組織）的數據，2018年全球整體報告的新增癌症病例約1,810萬例，死亡病例約960萬例。

然而，低收入和中等收入國家大眾對子宮頸癌的認知不足預計將在預測期內阻礙非專利抗癌無菌注射劑市場的成長。子宮頸癌是低收入和中等收入國家育齡婦女最常見的癌症之一。例如，根據國際癌症研究機構（IARC）2013年的報告，子宮頸癌在撒哈拉以南非洲的低收入國家最為普遍。

本報告的主要特點

本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
本文根據以下參數，介紹了全球非專利抗癌無菌注射藥物市場主要公司的概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、產品線更新、市場擴張和行銷策略做出明智的決策。
《全球非專利抗癌無菌注射藥物市場》報告針對該行業的各種相關人員，包括投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員可以透過分析全球非專利抗癌無菌注射劑市場中使用的各種策略矩陣來促進決策。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

公司簡介
- Eli Lilly &Company
- Biocon Ltd
- Baxter International Inc.
- Hikma Pharmaceuticals PLC
- Mylan NV
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc.

第9章

參考
分析方法

簡介目錄

Product Code: CMI562

Generic Oncology Sterile Injectables Market is estimated to be valued at USD 35.8 Bn in 2026 and is expected to reach USD 68.9 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 35.8 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.80%	2033 Value Projection:	USD 68.9 Bn

Generic oncology sterile injectables are used for the treatment of various types of cancers such as ovarian, breast, and lung. Generic oncology sterile injectables products are relatively cheaper than branded counterparts. Treatment cost is a major concern for cancer patients, especially in emerging economies such as India, Brazil, and China. Therefore, governments of such countries are taking efforts to reduce cost of medications and increase its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of few cancer products by 86% in March 2017.

Generic oncology sterile injectables have a huge potential in such countries, where patient population is high; however, spending power is relatively low. Furthermore, patent expiry of product is expected to fuel growth of the generic oncology sterile injectables market during the forecast period. The emergence of biosimilars have also impacted the growth of generics oncology sterile products. For instance, according to the Journal of Generics and Biosimilars Initiative, 2017, biosimilars have a major share in Europe and in the U.S. since 2013 and 2015, respectively, and the share of biosimilars is expected to increase significantly in the biologicals market. This is expected to eventually boost growth of the generic oncology sterile injectable market.

Market Dynamics

Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the World Health Organization, in 2018, around 18.1 Mn new cases of cancer and 9.6 Mn deaths were reported, globally.

However, lack of awareness amongst the people in low-income and middle-income countries regarding cervical cancer is expected to hinder growth of the generic oncology sterile injectables market during the forecast period. Cervical cancer is one of the most common cancers among women of reproductive age in low-income and middle-income countries. For instance, according to The International Agency for Research on Cancer's (IARC) report of 2013, cervical cancer is mostly prevalent in low-income countries of sub-Saharan Africa.

Key features of the study

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global generic oncology sterile injectable market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global generic oncology sterile injectable market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers of generic oncology sterile injectable market, research and consulting firms, new entrants, and financial analysts.

Market Segmentation

Global Generic Oncology Sterile Injectables Market, By Product Type
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
Global Generic Oncology Sterile Injectables Market, By Disease Indication
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
Global Generic Oncology Sterile Injectables Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Generic Oncology Sterile Injectables Market, By Region
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
Key Players
- Eli Lilly & Company
- Biocon Ltd
- Baxter International Inc.
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Scenario
Industry Trend
Merger and Acquisitions
New Product Approvals/Launch
Promotion and Marketing Initiatives
PEST Analysis

4. Global Generic Oncology Sterile Injectables Market, By Product Type, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2021 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Alkylating agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Plant Alkaloids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Antitumor Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Peptide Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Generic Oncology Sterile Injectables Market, By Disease Indication, 2021- 2033, (USD Bn)

Introduction
- Market Share Analysis, 2021 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Pancreatic Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Generic Oncology Sterile Injectables Market, By Distribution Channel, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2021 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Generic Oncology Sterile Injectables Market, By Region, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2021 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2021 - 2026
- Regional Trends
North America
- Market Size and Forecast, By Product Type, 2021 - 2033 , (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - U.S.
  - Canada
Europe
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Company Profiles
- Eli Lilly & Company
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Biocon Ltd
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Baxter International Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Hikma Pharmaceuticals PLC
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Mylan N.V.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Sandoz International GmbH
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
  - Analyst Views